Loading...
Loading...
- Battered after a surprising FDA rejection for its lead pipeline program last week, Akebia Therapeutics Inc AKBA has layoffs that are now on the way.
- In a filing with the SEC, Akebia said the FDA issued a partial clinical hold on the drug's pediatric studies.
- As a result, Akebia will suspend all vadadustat studies in children.
- According to the filing, Akebia approved a 42% reduction in its staff. Akebia expects to complete the layoffs rather quickly, noting that the process should be completed by the second quarter.
- The layoffs represent Akebia's effort to "refocus its strategic priorities around its commercial product, Auryxia, and its development portfolio."
- The Company expects to record a one-time restructuring charge of approximately $12 million in Q2 of 2022.
- The reduction in force will result in an approximate $60 million - 65 million reduction in net cash required for operating activities through the end of 2023.
- For Akebia, the layoffs and partial hold also came after the biotech put together $85 million to commercialize vadadustat in a reorganized deal with Vifor Pharma.
- Vifor agreed to an additional equity purchase of $20 million. Further, an accelerated $25 million milestone and $40 million in refundable working capital.
- Price Action: AKBA shares are down 2.49% at $0.56 during the market session on the last check Thursday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in